New Zealand markets close in 5 hours 22 minutes

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
215.74+7.04 (+3.37%)
At close: 04:00PM EST
214.00 -1.74 (-0.81%)
After hours: 05:22PM EST
Full screen
Trade prices are not sourced from all markets
Previous close208.70
Open209.10
Bid212.00 x 1100
Ask215.91 x 800
Day's range206.02 - 217.48
52-week range173.45 - 371.16
Volume1,475,638
Avg. volume1,183,608
Market cap33.936B
Beta (5Y monthly)1.13
PE ratio (TTM)48.59
EPS (TTM)4.44
Earnings date07 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est243.50
  • Financial Times

    Illumina boosts spending on US lobbying amid opposition to Grail acquisition

    Illumina sharply increased its spending on lobbying over the past two years as it tried to build support against antitrust regulators in the US and Europe that have attempted to block its $8bn acquisition of cancer testing company Grail. The world’s biggest genome sequencing company and its subsidiary Grail spent a combined $14.6mn in 2021 and 2022 on federal lobbying in the US, more than five times the $2.72mn combined they spent in the previous two years, according to public disclosures. Illumina was the fourth-largest spender on lobbying among biotech and pharma companies in 2022 at $9.4mn, behind only Pfizer, Roche and Amgen, which are much larger companies, according to an analysis by OpenSecrets, a transparency group.

  • Zacks

    Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?

    Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zacks

    Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for

    Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.